Arginine: Appropriate dose and delivery environment makes it an anticancer molecule

Open Cancer Journal

Volumn 3, Issue 1, 2009, Pages 1-15

  Shukla, Jyoti ^a   Thakur, V S ^a   Poduval, T B ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

Anticancer; Arginine; Delivery; Loco regional therapy; Membrane damage; Non metabolic; Pharmacological dose

Indexed keywords

AGMATINE; ARGININE; DEXTRO ARGININE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CELL STRAIN 3T3; CHIRALITY; DRUG DOSE; ERYTHROCYTE; FIBROSARCOMA; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOSARCOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 77953792881     PISSN: None     EISSN: 18740790     Source Type: Journal    
DOI: 10.2174/1874079001003010001     Document Type: Article

References (37)

1. Grillo MA, Colombatto S. Arginine revisited: minireview article. Amino Acids 2004; 26: 345-51.
2. Lind DS. Arginine and cancer. J Nutr 2004; 134: 2837-41.
3. Tong BC, Barbul A. Cellular and physiological effects of arginine. Mini Rev Med Chem 2004; 4: 823-32.
4. Wu G. Amino acids: metabolism, functions and nutrition. Amino Acids 2009; 37: 1-17.
5. Agostinelli E, Bachrach U. Polyamines and their analogs in cancer and other diseases. Amino Acids 2007; 33: 173.
6. Nanthakumaran S, Brown I, Steven DH, Schofield AC. Inhibition of gastric cancer cell growth by arginine: Molecula mechanisms of action. Clin Nutr 2009; 28: 65-70.
7. Wolf C, Bruss M, Hanisch B, et al. Molecular basis for the antiproliferative effect of agmatine in tumor cells of colonic, hepatic and neuronal origin. Mol Pharmacol 2007; 71: 276-83.
8. Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharmacol 2009; 625: 190-4.
9. Bhutia SK, Maiti TK. Targeting tumors with peptides from natural sources. Trends Biotechnol 2008; 26: 210-7.
10. Chabner BA, Roberts TG, Jr. Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5: 65-72.
11. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochem Biophy Acta 2008; 1778: 357-75.
12. Dandan Y, Guoming L, Gao L, Wei L. Interaction of arginine oligomer with model membrane. Biochem Biophys Res Commun 2007; 359: 1024-9.
13. Dennison SR, Whittaker M, Harris F, Phoenix DA. Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumor cell membranes. Curr Protein Pept Sci 2006; 7: 487-99.
14. Mader JS, Hoskin DW. Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment. Expert Opin Investig Drugs 2006; 15: 933-46.
15. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
16. Lemeshko VV. Potential-dependent membrane permeabilization and mitochondrial aggregation caused by anticancer polyarginine- KLA peptides. Arch Biochem Biophys 2010; 493: 213-20.
17. Janin YL. Peptides with anticancer use or potential. Amino Acids 2004; 25: 1-40.
18. Das U, Hariprasad G, Ethayathulla AS, et al. Inhibition of protein aggregation: Supramolecular assemblies of arginine hold the key. PLoS One 2007; 11: e1176.
19. Toyama N, Kohno J, Mafune F, Kondow T. Solvation structure of arginine in aqueous solution studied by liquid beam technique. Chem Phys Lett 2006; 419: 369-73.
20. Shukla Jyoti, Thakur VS, Poduval TB. Arginine magic: Arginine kills tumor cells when presented in saline. FASEB J 2008; 22: 1198.5.
21. Thakur VS, Shankar B, Chatterjee S, Premachandran S, Sainis KB. Role of tumor-derived transforming growth factor-β1 (TGF- β1) in site-dependent tumorigenicity of murine ascitic lymphosarcoma. Cancer Immunol Immunother 2005; 54: 837-47.
22. Poduval TB, Seshadri M, Sundaram K. Lectin potentiation of BCGcontact- mediated antitumor action. J Natl Cancer Inst (Bethesda) 1984; 65: 909-12.
23. Zons Von P, Crowley-Nowick P, Friberg D, et al. Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma. Clin Diagn Lab Immunol 1997; 2: 202-7.
24. Chatterjee S, Premachandran S, Bagewadikar RS, Poduval TB. The use of ELISA to monitor amplified hemolysis by the combined action of osmotic stress and radiation: potential applications. Radiat Res 2005; 163: 351-5.
25. Ailenberg M, Silverman M. Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: implications for use of TSA in cancer therapy. Biochem Biophy Res Commun 2003; 302: 181-5.
26. Cairns R, Papandreou I, Denko N. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 2006; 4: 61-70.
27. Minchinton AI, Tannock IF. Drug penetration in solid tumors. Nat Rev Cancer 2006; 6: 583-92.
28. Fung-Kee-Fung M, Provencher D, Rosen B, et al. Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care. Gynecol Oncol 2007; 105: 747-56.
29. Celikoglu F, Celikoglu SI, Goldberg EP. Bronchoscopic intratumor chemotherapy of lung cancer. Lung Cancer 2008; 61: 1-12.
30. Boger RH, Bode-Boger SM. The clinical pharmacology of Larginine. Annu Rev Pharmacol Toxicol 2001; 41: 79-99.
31. Marietta M, Facchinetti F, Neri I, Piccinini F, Volpe A, Torelli G. L-arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. Thromb Res 1997; 88: 229-35.
32. Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115: 616-23.
33. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumor xenograft: molecular charge dependence. Br J Cancer 2000; 82: 1513-8.
34. Gruber J. Analysis of hydrophobic potential on molecular surfaces. Laboratory of Molecular Biophysics 2000. Available from: http://biop.ox.acuk/www/lj2000/noble_02.html
35. Mitaku S, Hirokawa T, Tsuji T. Amphiphilicity index of polar amino acids as an aid in the characterization of amino acid preference at membrane-water interfaces. Bioinformatics 2002; 18: 608-16.
36. Strom MB, Haug BE, Skar ML, et al. The pharmacophore of short cationic antibacterial peptides. J Med Chem 2003; 46: 1567-70.
37. Bevan HL, Nguyen NP, Vinh-Hung V, Rapiti E, Vlastos G. Locoregional treatment in metastatic breast can patients: Is there a survival benefit? Breast Cancer Res Treat 2010; 119: 537-45.